Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
Gideon Schreiber
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

COVID-19 vaccine side effects: The positives about feeling bad
Jonathan Sprent, Charles M. King
Science Immunology (2021) Vol. 6, Iss. 60
Open Access | Times Cited: 114
SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon
Maya Shemesh, Turgut E. Aktepe, Joshua M. Deerain, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 8, pp. e1009800-e1009800
Open Access | Times Cited: 112
SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney
Magen E. Francis, Una Goncin, Andrea Kroeker, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 7, pp. e1009705-e1009705
Open Access | Times Cited: 82
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients
Marco Contoli, Alberto Papi, Luca Tomassetti, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 72
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Xi Zhou, Qing Ye
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 69
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Alexander Norman, Charlotte Franck, Mary Christie, et al.
ACS Central Science (2021) Vol. 7, Iss. 6, pp. 1001-1008
Open Access | Times Cited: 68
Overview of Neutralizing Antibodies and Their Potential in COVID-19
José Javier Morales‐Núñez, José Francisco Muñoz‐Valle, Paola Carolina Torres-Hernández, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1376-1376
Open Access | Times Cited: 67
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
Anneliese S. Ashhurst, Arthur H. Tang, Pavla Fajtová, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2956-2970
Open Access | Times Cited: 65
Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron
Zhenlu Chong, Courtney E. Karl, Peter Halfmann, et al.
Cell Reports (2022) Vol. 39, Iss. 6, pp. 110799-110799
Open Access | Times Cited: 63
Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
Megen C Wittling, Shannon R. Cahalan, Eric A. Levenson, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 59
Type I Interferon Production of Plasmacytoid Dendritic Cells under Control
Dóra Bencze, Tünde Fekete, Kitti Pázmándi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4190-4190
Open Access | Times Cited: 58
Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Jason Johansen‐Leete, Sven Ullrich, Sarah E. Fry, et al.
Chemical Science (2022) Vol. 13, Iss. 13, pp. 3826-3836
Open Access | Times Cited: 48
Trained Immunity: An Overview and the Impact on COVID-19
Justin M. Brueggeman, Juan Zhao, Madison Schank, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19
Ingrid Fricke-Galindo, Alfonso Martínez-Morales, Leslie Chávez‐Galán, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
The crucial regulatory role of type I interferon in inflammatory diseases
Ling Ji, Tianle Li, Huimin Chen, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 26
Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators
Daniela Ricci, Marilena P. Etna, Fabiana Rizzo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 7017-7017
Open Access | Times Cited: 54
Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19
Anna E. Spiering, Teun J. de Vries
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination
Vignesh Narayanaswamy, Brian T. Pentecost, Corina N. Schoen, et al.
Obstetrics and Gynecology (2021) Vol. 139, Iss. 2, pp. 181-191
Open Access | Times Cited: 52
Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model
Pierre Bessière, Marine Wasniewski, Evelyne Picard‐Meyer, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 8, pp. e1009427-e1009427
Open Access | Times Cited: 51
A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19
Shaghayegh Khanmohammadi, Nima Rezaei, Mehdi Khazaei, et al.
Journal of Clinical Immunology (2021) Vol. 42, Iss. 1, pp. 19-24
Open Access | Times Cited: 50
An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
Mohammad Enamul Hoque Kayesh, Michinori Kohara, Kyoko Tsukiyama–Kohara
Viruses (2021) Vol. 13, Iss. 11, pp. 2302-2302
Open Access | Times Cited: 46
Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis
Rafaela Pires da Silva, João Ismael Budelon Gonçalves, Rafael Fernandes Zanin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 43
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility
Sandra Smieszek, Vasilios M. Polymeropoulos, Changfu Xiao, et al.
Journal of Global Antimicrobial Resistance (2021) Vol. 26, pp. 239-240
Open Access | Times Cited: 40
Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2
Jiajing Zheng, Jiameng Miao, Rui Guo, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 36
Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 Genes Are Associated with Worse Clinical Outcomes in COVID-19
Cristine Dieter, Letícia de Almeida Brondani, Natália Emerim Lemos, et al.
Genes (2022) Vol. 14, Iss. 1, pp. 29-29
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top